Uekawa Ayano, Kurahashi Ryoma, Motoshima Takanobu, Murakami Yoji, Yatsuda Junji, Kamba Tomomi
Department of Urology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Urol Case Rep. 2022 Aug 24;45:102198. doi: 10.1016/j.eucr.2022.102198. eCollection 2022 Nov.
A 46-year-old man developed a right renal tumor with multiple lung and hilar lymph node metastases. Laparoscopic radical nephrectomy was performed, and clear cell renal cell carcinoma was diagnosed 6 years earlier. Despite the use of available systemic therapeutic agents, atelectasis in the right upper lobe due to a pulmonary hilar mass and brain metastases reduced his performance, and he was becoming terminally ill. After administration of avelumab plus axitinib as 9th-line therapy, significant shrinkage of the metastases and improvement in performance status were observed. This case indicates the possibility of using avelumab plus axitinib as late-line therapy.
一名46岁男性患右肾肿瘤并伴有多发肺及肺门淋巴结转移。6年前接受了腹腔镜根治性肾切除术,诊断为透明细胞肾细胞癌。尽管使用了现有的全身治疗药物,但由于肺门肿块导致的右上叶肺不张和脑转移使他的身体状况下降,病情逐渐恶化。在接受阿维鲁单抗联合阿昔替尼作为第九线治疗后,转移灶明显缩小,身体状况得到改善。该病例表明阿维鲁单抗联合阿昔替尼作为晚期治疗的可能性。